Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases
Newly identified pathway may explain the so-called niacin paradox
It's time to increase testing for this major cardiovascular risk factor in advance of new therapies
Undetectable levels achieved for nearly nine months in phase 1 trial
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Randomized controlled study undercuts unsubstantiated ‘heart health’ claims
Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor
Preclinical models focus interest on the protein hepsin
New phase 2 data boost hopes for phase 3 Lp(a) HORIZON trial
Large cohort study also finds familial chlyomicronemia syndrome less rare than thought
ACCELERATE substudy shows no benefit of evacetrapib in patients with diabetes